iBio, Inc. (IBIO)

NYSEAMERICAN: IBIO · IEX Real-Time Price · USD
4.060
+0.700 (20.83%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States.

It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.

The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever.

iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever.

The company was incorporated in 2008 and is headquartered in Bryan, Texas.

iBio, Inc.
iBio, Inc. logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 26
CEO Dr. Martin B. Brenner D.V.M., Ph.D.

Contact Details

Address:
600 Madison Avenue, Suite 1601
New York, New York 10022-1737
United States
Phone 302 355-0650
Website ibioinc.com

Stock Details

Ticker Symbol IBIO
Exchange NYSEAMERICAN
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001420720
CUSIP Number 451033203
ISIN Number US4510337086
Employer ID 26-2797813
SIC Code 2834

Key Executives

Name Position
Dr. Martin B. Brenner D.V.M., Ph.D. Chief Executive Officer and Chief Scientific Officer
Felipe Duran Chief Financial Officer
Stephen Kilmer Investor Relations Officer
Marc Banjak J.D. General Counsel
Robert B. Kay Interim Secretary and Interim Treasurer

Latest SEC Filings

Date Type Title
Feb 26, 2024 8-K Current Report
Feb 21, 2024 8-K Current Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 10-Q Quarterly Report
Jan 19, 2024 8-K Current Report
Jan 10, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jan 8, 2024 8-K Current Report
Jan 4, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Dec 26, 2023 8-K Current Report
Dec 8, 2023 8-K Current Report